Pier Franco Conte

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Gadducci Angiolo; Katsaros Dionyssios; Zola Paolo; Scambia Giovanni; Ballardini Michela; Pasquini Enzo; Fertonani Carlo; Maggi Lorenzo; Pecorelli Sergio; Conte Pier Franco;
Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2).
Bengala C; Bettelli S; Bertolini F; Salvi S; Chiara S; Sonaglio C; Losi L; Bigiani N; Sartori G; Dealis C; Malavasi N; D'Amico R; Luppi G; Gatteschi B; Maiorana A; Conte P F
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.
Bertolini Federica; Chiara Silvana; Bengala Carmelo; Antognoni Paolo; Dealis Cristina; Zironi Sandra; Malavasi Norma; Scolaro Tindaro; Depenni Roberta; Jovic Gordana; Sonaglio Claudia; Rossi Aldo; Luppi Gabriele; Conte Pier Franco
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Pier Franco Conte (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Gadducci Angiolo; Katsaros Dionyssios; Zola Paolo; Scambia Giovanni; Ballardini Michela; Pasquini Enzo; Fertonani Carlo; Maggi Lorenzo; Pecorelli Sergio; Conte Pier Franco;
Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(4):615-9.
2009: Bengala C; Bettelli S; Bertolini F; Salvi S; Chiara S; Sonaglio C; Losi L; Bigiani N; Sartori G; Dealis C; Malavasi N; D'Amico R; Luppi G; Gatteschi B; Maiorana A; Conte P F
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(3):469-74.
2009: Bertolini Federica; Chiara Silvana; Bengala Carmelo; Antognoni Paolo; Dealis Cristina; Zironi Sandra; Malavasi Norma; Scolaro Tindaro; Depenni Roberta; Jovic Gordana; Sonaglio Claudia; Rossi Aldo; Luppi Gabriele; Conte Pier Franco
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
International journal of radiation oncology, biology, physics 2009;73(2):466-72.
2009: Malavasi Norma; Ponti Giovanni; Depenni Roberta; Bertolini Federica; Zironi Sandra; Luppi Gabriele; Conte Pier Franco
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.
Journal of hematology & oncology 2009;2():35.
2008: Gadducci A; Conte P F
Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(5):943-53.
2008: Frassoldati Antonio; Guarneri Valentina; Piacentini Federico; Jovic Gordana; Giovannelli Simona; Oliva Cristina; Conte Pier Franco
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Clinical breast cancer 2008;8(1):97-100.
2007: Bertolini Federica; Bengala Carmelo; Losi Luisa; Pagano Maria; Iachetta Francesco; Dealis Cristina; Jovic Gordana; Depenni Roberta; Zironi Sandra; Falchi Anna Maria; Luppi Gabriele; Conte Pier Franco
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
International journal of radiation oncology, biology, physics 2007;68(5):1455-61.
2007: Gelmini Roberta; Bertolini Federica; Rossi Giulio; Luppi Gabriele; Saviano Massimo; Conte Pier Franco
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): is it still a courageous choice? Report of two cases.
Surgical laparoscopy, endoscopy & percutaneous techniques 2007;17(2):133-7.
2006: Losi Lorena; Luppi Gabriele; Gavioli Margherita; Iachetta Francesco; Bertolini Federica; D'Amico Roberto; Jovic Gordana; Bertoni Filippo; Falchi Anna Maria; Conte Pier Franco
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy.
International journal of colorectal disease 2006;21(7):645-51.
2006: Marangolo Maurizio; Bengala Carmelo; Conte Pier Franco; Danova Marco; Pronzato Paolo; Rosti Giovanni; Sagrada Paola
Dose and outcome: the hurdle of neutropenia (Review).
Oncology reports 2006;16(2):233-48.
2006: Maur M; Guarneri V; Frassoldati A; Conte P F
Primary systemic therapy in operable breast cancer: clinical data and biological fall-out.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v158-64.
2006: Tibaldi C; Prochilo T; Russo F; Pennucci M C; Del Freo A; Innocenti F; Fabbri A; Falcone A; Conte P F; Baldini E
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
British journal of cancer 2006;94(9):1263-6.
2006: Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte P F;
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
British journal of cancer 2006;94(7):1016-20.
2006: Cazzaniga Marina E; Dogliotti Luigi; Cascinu Stefano; Barni Sandro; Labianca Roberto; Chiara Silvana; Conte Pier Franco; Gasparini Giampietro; Pasetto Lara; Torri Valter
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study.
Oncology 2006;71(5-6):374-81.
2005: Guarneri Valentina; Donati Sara; Nicolini Massimiliano; Giovannelli Simona; D'Amico Roberto; Conte Pier Franco
Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.
The oncologist 2005;10(10):842-8.
2005: Frassoldati Antonio; Maur Michela; Guarneri Valentina; Nicolini Massimiliano; Conte Pier Franco
Predictive value of biologic parameters for primary chemotherapy in operable breast cancer.
Clinical breast cancer 2005;6(4):315-24.
2005: Gavioli Margherita; Luppi Gabriele; Losi Lorena; Bertolini Federica; Santantonio Mario; Falchi Anna Maria; D'Amico Roberto; Conte Pier Franco; Natalini Gianni
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.
Diseases of the colon and rectum 2005;48(10):1851-7.
2005: Conte P F; Donati S; Gennari A; Guarneri V; Orlandini C; Rondini M; Roncella M; Marini L; Collecchi P; Viacava P; Naccarato A G; Degli Esposti R; Bonardi S; Bottini A; Saracchini S; Tumolo S; Gullo G; Santoro A; Crino L
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
British journal of cancer 2005;93(4):406-11.
2005: Gadducci Angiolo; Cosio Stefania; Conte Pier Franco; Genazzani Andrea Riccardo
Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.
Critical reviews in oncology/hematology 2005;55(2):153-66.
2005: Bengala C; Guarneri V; Giovannetti E; Lencioni M; Fontana E; Mey V; Fontana A; Boggi U; Del Chiaro M; Danesi R; Ricci S; Mosca F; Del Tacca M; Conte P F
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.
British journal of cancer 2005;93(1):35-40.
2005: Bengala C; Guarneri V; Ledermann J; Rosti G; Wandt H; Lotz J-P; Cure J H; Orlandini C; Ferrante P; Conte P F; Demirer T;
High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).
Bone marrow transplantation 2005;36(1):25-31.
2005: Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso A M; Pegna A Lopes; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte P F; Falcone A;
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Lung cancer (Amsterdam, Netherlands) 2005;48(1):121-7.
2004: Guarneri V; Bengala C; Orlandini C; Gennari A; Donati S; Campani D; Collecchi P; Maur M; Conte P F
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
Bone marrow transplantation 2004;34(5):413-7.
2004: Conte Pier Franco; Guarneri Valentina; Bruzzi Paolo; Prochilo Tiziana; Salvadori Barbara; Bolognesi Angelo; Aldrighetti Daniela; Venturini Marco; Rosso Riccardo; Mammoliti Serafina; Carnino Flavio; Giannessi Piergiorgio; Costantini Massimo; Moyano Alfredo; Baldini Editta;
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Cancer 2004;101(4):704-12.
2004: Baldini E; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Carnino F; Gallo L; Giannessi P; Conte P F; Orlandini C; Bruzzi P
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
British journal of cancer 2004;91(1):45-9.
2004: Guarneri Valentina; Conte Pier Franco
The curability of breast cancer and the treatment of advanced disease.
European journal of nuclear medicine and molecular imaging 2004;31 Suppl 1():S149-61.
2004: Allegrini Giacomo; Falcone Alfredo; Di Marsico Roberta; Lencioni Monica; Masi Gianluca; Galli Costanza; Cupini Samanta; Pfanner Elisabetta; Marcucci Lorenzo; Conte Pier Franco
5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.
American journal of clinical oncology 2004;27(1):101-5.
2004: Cappuzzo F; Mazzoni F; Gennari A; Donati S; Salvadori B; Orlandini C; Cetto G L; Molino A; Galligioni E; Mansutti M; Tumolo S; Lucentini A; Valduga F; Bartolini S; Crinò L; Conte P F
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
British journal of cancer 2004;90(1):31-5.
2003: Gadducci Angiolo; Cosio Stefania; Fanucchi Antonio; Nardini Vincenzo; Roncella Manuela; Conte Pier Franco; Genazzani Andrea Riccardo
Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature.
Anticancer research 2003;23(6D):5225-9.
2003: Romanini A; Tanganelli L; Carnino F; Fanucchi A; Lionetto R; Pastorino S; Cosio S; Gadducci A; Conte P F
First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients.
Gynecologic oncology 2003;89(3):354-9.
2003: Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte P F
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bone marrow transplantation 2003;31(4):275-80.
2003: Baldini E; Gardin G; Giannessi P G; Evangelista G; Roncella M; Prochilo T; Collecchi P; Rosso R; Lionetto R; Bruzzi P; Mosca F; Conte P F
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):227-32.
2003: Gadducci A; Cosio S; Fanucchi A; Tanganelli L; Conte P F; Cristofani R; Genazzani A R
Is pretreatment hemoglobin level a predictor of complete response to salvage chemotherapy for recurrent platinum-pretreated ovarian carcinoma?
European journal of gynaecological oncology 2003;24(5):405-10.
2002: Gennari Alessandra; Guarneri Valentina; Landucci Elisabetta; Orlandini Cinzia; Rondini Marianna; Salvadori Barbara; Ricci Sergio; Conte Pier Franco
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Clinical breast cancer 2002;3(5):346-52.
2002: Fogli S; Danesi R; Gennari A; Donati S; Conte P F; Del Tacca M
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(6):919-27.
2002: Danesi Romano; Innocenti Federico; Fogli Stefano; Gennari Alessandra; Baldini Editta; Di Paolo Antonello; Salvadori Barbara; Bocci Guido; Conte Pier Franco; Del Tacca Mario
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
British journal of clinical pharmacology 2002;53(5):508-18.
2001: Baldini E; Ardizzoni A; Prochilo T; Cafferata M A; Boni L; Tibaldi C; Neumaier C; Conte P F; Rosso R;
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
British journal of cancer 2001;85(10):1452-5.
2001: Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte P F; Del Tacca M
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1301-6.
2001: Consolini R; Calleri A; Bengala C; Legitimo A; Conte P F
Evaluation of thrombopoiesis kinetics by measurement of reticulated platelets and CD34(+) cell subsets in patients with solid tumors following high dose chemotherapy and autologous peripheral blood progenitor cell support.
Haematologica 2001;86(9):959-64.
2001: Conte P F; Gennari A; Donati S; Salvadori B; Baldini E; Bengala C; Pazzagli I; Orlandini C; Danesi R; Fogli S; Del Tacca M
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Breast cancer research and treatment 2001;68(2):171-9.
2001: Bengala C; Pazzagli I; Innocenti F; Donati S; Favre C; Menconi M C; Greco F; Danesi R; Orlandini C; Guarneri V; Del Tacca M; Conte P F
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(1):69-74.
2001: Chiara S; Lionetto R; Vincenti M; Bruzzone M; Nobile M T; Gadducci A; Carnino F; Rosso R; Conte P F
Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy.
Critical reviews in oncology/hematology 2001;37(1):27-34.
2001: Conte P F; Gadducci A; Cianci C
Second-line treatment and consolidation therapies in advanced ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11 Suppl 1():52-6.
2000: Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte P F; Genazzani A R
p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
Anticancer research 2000;20(6C):4793-9.
2000: Conte P F; Gennari A; Landucci E; Orlandini C
Role of epirubicin in advanced breast cancer.
Clinical breast cancer 2000;1 Suppl 1():S46-51.
2000: Orlandini C; Amunni G; Conte P F; Francini G; Rossini G C; Vanni D;
[Experimentation with Di Bella polychemotherapy in Tuscany]
Epidemiologia e prevenzione 2000;24(5):209-12.
2000: Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte P F
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1127-30.
2000: Lencioni M; Falcone A; Allegrini G; Pfanner E; Masi G; Brunetti I; Di Marsico R; Fontana E; Orlandini C; Stampino C G; Bartolozzi C; Conte P F
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.
Oncology 2000;59(3):204-9.
2000: Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte P F
Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
American journal of clinical oncology 2000;23(4):412-5.
2000: Bocci G; Danesi R; Di Paolo A D; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte P F; Del Tacca M
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3032-7.
2000: Gennari A; Donati S; Salvadori B; Giorgetti A; Salvadori P A; Sorace O; Puccini G; Pisani P; Poli M; Dani D; Landucci E; Mariani G; Conte P F
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Clinical breast cancer 2000;1(2):156-61; discussion 162-3.
2000: Gennari A; Donati S; Danesi R; Fogli S; Orlandini C; Del Tacca M; Conte P F
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Seminars in oncology 2000;27(1 Suppl 2):14-9.
2000: Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Algeri R; Bonifazi V; Fioretto M L; Orlandini C; Conte P F
Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
Lung cancer (Amsterdam, Netherlands) 2000;27(2):75-80.
2000: Ardizzoni A; Antonelli G; Ricci S; Frasci G; Rinaldi M; Boni L; Galletti P; Pennucci M C; Antonuzzo A; Gravina A; Galli L; Comella G; Conte P F; Salvati F; Rosso R
Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study.
American journal of clinical oncology 2000;23(1):22-5.
2000: Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte P F
Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gynecologic oncology 2000;76(2):157-62.
2000: Conte P F; Cianci C; Tanganelli L; Gadducci A
Ovarian cancer: optimal chemotherapy in relapsed disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():145-50.
1999: Bertuccelli M; Falcone A; Campoccia S; Conti M; Brunetti I; Caramella D; Giulianotti P C; Mosca F; Bartolozzi C; Conte P F
Intrahepatic chemotherapy with floxuridine, leucovorin and dexamethasone in continuous infusion and mitomycin-C bolus in unresectable hepatic metastases from colorectal cancer: a phase II study.
Tumori 1999;85(6):473-7.
1999: Gennari A; Salvadori B; Donati S; Bengala C; Orlandini C; Danesi R; Del Tacca M; Bruzzi P; Conte P F
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3596-602.
1999: Conte P F; Cianci C; Gadducci A
Up date in the management of advanced ovarian carcinoma.
Critical reviews in oncology/hematology 1999;32(1):49-58.
1999: Danesi R; Conte P F; Del Tacca M
Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
Clinical pharmacokinetics 1999;37(3):195-211.
1998: Falcone A; Pfanner E; Brunetti I; Allegrini G; Lencioni M; Galli C; Masi G; Danesi R; Antonuzzo A; Del Tacca M; Conte P F
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy.
Tumori 1998;84(6):666-8.
1998: Collecchi P; Baldini E; Giannessi P; Naccarato A G; Passoni A; Gardin G; Roncella M; Evangelista G; Bevilacqua G; Conte P F
Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1701-4.
1998: Bengala C; Pazzagli I; Tibaldi C; Favre C; Vanacore R; Greco F; Mazzoni A; Menconi M C; Macchia P; Conte P F
Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
Cancer 1998;82(5):867-73.
1998: Conte P F; Gennari A; Salvadori B; Pazzagli C; Bengala C
Paclitaxel plus epirubicin in advanced breast cancer.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 1):40-4.
1997: Baldini E; Gardin G; Giannessi P; Brema F; Camorriano A; Carnino F; Naso C; Pastorino G; Pronzato P; Rosso R; Rubagotti A; Torretta G; Conte P F
A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy.
Tumori 1997;83(5):829-33.
1997: Michelotti A; Salvadori B; Donati S; Tognoni A; Tibaldi C; Conte P F
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients.
Tumori 1997;83(5):826-8.
1997: Conte P F; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2510-7.
1997: Falcone A; Lencioni M; Brunetti I; Pfanner E; Allegrini G; Antonuzzo A; Andreuccetti M; Malvaldi G; Danesi R; Del Tacca M; Conte P F
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(6):539-45.
1997: Bruzzone M; Rubagotti A; Gadducci A; Catsafados E; Foglia G; Brunetti I; Giannessi P G; Carnino F; Iskra L; Rosso R; Martoni A; Pannuti F; De Lisi V; Maltoni R; Ridolfi R; Mammoliti S; Gallo L; Boccardo F; Ragni N; Conte P F
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest.
Gynecologic oncology 1997;65(3):499-505.
1997: Carnino F; Fuda G; Ciccone G; Iskra L; Guercio E; Dadone D; Conte P F
Significance of lymph node sampling in epithelial carcinoma of the ovary.
Gynecologic oncology 1997;65(3):467-72.
1997: Bertuccelli M; Cartei F; Falcone A; Campoccia S; Sainato A; Ducci F; Moda S; Pfanner E; Lencioni M; Brunetti I; Giulianotti P C; Mosca F; Laddaga M; Conte P F
Postoperative adjuvant chemoradiotherapy for rectal cancer: analysis of acute and chronic toxicity.
Tumori 1997;83(2):599-603.
1996: Conte P F; Baldini E; Michelotti A; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Giannessi P G; Gentile A
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
Seminars in oncology 1996;23(6 Suppl 15):39-42.
1996: Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina R C; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte P F; Rosso R
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3112-20.
1996: Baldini E; Tibaldi C; Pfanner E; Ricci S; Falcone A; Ceribelli A; Sarcina R; Comella G; Stampino C G; Conte P F
Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer.
American journal of clinical oncology 1996;19(6):592-4.
1996: Gennari A; Salvadori B; Tognoni A; Conte P F
Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):978-9.
1996: Michelotti A; Gennari A; Salvadori B; Tognoni A; Tibaldi C; Baldini E; Conte P F
Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):857-60.
1996: Michelotti A; Gennari A; Salvadori B; Giannessi P G; Baldini E; Tibaldi C; Da Prato M; Conte P F
Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Seminars in oncology 1996;23(5 Suppl 11):38-40.
1996: Conte P F; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Seminars in oncology 1996;23(5 Suppl 11):28-31.
1996: Tibaldi C; Baldini E; Ricci S; Conte P F
A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer.
Anticancer research 1996;16(5B):3213-5.
1996: Baldini E; Tibaldi C; Chella A; Angeletti C A; Silvano G; Andrei A; Algeri R; Conte P F
Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(7):747-9.
1996: Conte P F; Latreille J; Mauriac L; Calabresi F; Santos R; Campos D; Bonneterre J; Francini G; Ford J M
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2552-9.
1996: Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti P C; Vannucci L; Mosca F; Conte P F
Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(6):601-5.
1996: Conte P F; Baldini E; Gardin G; Pronzato P; Amadori D; Carnino F; Monzeglio C; Gentilini P; Gallotti P; DeMicheli R; Venturini M; Rubagotti A; Rosso R
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):487-90.
1996: Andreuccetti M; Allegrini G; Antonuzzo A; Malvaldi G; Conte P F; Danesi R; Del Tacca M; Falcone A
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks.
European journal of cancer (Oxford, England : 1990) 1996;32A(7):1219-26.
1996: Collecchi P; Giannessi P G; Baldini E; Naccarato A G; Passoni A; Bevilacqua G; Conte P F
Effects of primary chemotherapy on biological parameters of locally advanced breast cancer.
Annals of the New York Academy of Sciences 1996;784():419-26.
1996: Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell A B; Conte P F
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):729-36.
1996: Conte P F; Bruzzone M; Carnino F; Gadducci A; Algeri R; Bellini A; Boccardo F; Brunetti I; Catsafados E; Chiara S; Foglia G; Gallo L; Iskra L; Mammoliti S; Parodi G; Ragni N; Rosso R; Rugiati S; Rubagotti A
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):351-6.
1996: Conte P F; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi P G; Gentile A; Biadi O; Mariani M
Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Seminars in oncology 1996;23(1 Suppl 1):28-32.
1996: Repetto L; Giannessi P G; Campora E; Pronzato P; Vigani A; Naso C; Spinelli I; Conte P F; Rosso R
Tamoxifen and interferon-beta for the treatment of metastatic breast cancer.
Breast cancer research and treatment 1996;39(2):235-8.
1995: Del Mastro L; Venturini M; Giannessi P G; Vigani A; Garrone O; Carnino F; Russo P; Galletti P; Rosso R; Conte P F
Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites: a feasibility study.
Anticancer research 1995;15(5B):2207-12.
1995: Falcone A; Pfanner E; Cianci C; Danesi R; Brunetti I; Del Tacca M; Conte P F
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Cancer 1995;75(2):440-3.
1995: Chiara S; Lionetto R; Campora E; Oliva C; Merlini L; Bruzzi P; Rosso R; Conte P F
Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest.
European journal of cancer (Oxford, England : 1990) 1995;31A(3):296-301.
1994: Baldini E; Giannessi P G; Gardin G; Alama A; Minuto F; Barreca A; Conte P F
In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma.
Journal of biological regulators and homeostatic agents 1994;8(4):113-6.
1994: Baldini E; Tibaldi C; Chella A; Angeletti C A; Romanini A; Andrei A; Algeri R; Silvano G; Conte P F
Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer.
Seminars in oncology 1994;21(3 Suppl 4):12-5.
1994: Brunetti I; Falcone A; Bertuccelli M; Cianci C; Ricci S; Conte P F
Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
American journal of clinical oncology 1994;17(3):210-4.
1994: Falcone A; Cianci C; Pfanner E; Bertuccelli M; Brunetti I; Muttini M P; Dargenio F; Ricci S; Conte P F
Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):291.
1994: Falcone A; Danesi R; Zaccaro L; Pieracci D; Pfanner E; Cianci C; Andreuccetti M; Malvaldi G; Del Tacca M; Conte P F
Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies.
European journal of cancer (Oxford, England : 1990) 1994;30A(4):516-20.
1994: Alama A; Chiara S; Merlo F; Ragni N; Conte P F; Meazza R; Reggiardo G; Ferrari I; Rosso R
Tumour kinetics, response to chemotherapy and survival in primary ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(4):449-52.
1994: Conte P F; Giannessi P G; Latreille J; Mauriac L; Koliren L; Calabresi F; Ford J M
Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 7():S41-4.
1994: Gadducci A; Brunetti I; Muttini M P; Fanucchi A; Dargenio F; Giannessi P G; Conte P F
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(10):1432-5.
1993: Pronzato P; Bertelli G; Gardin G; Rubagotti A; Conte P F; Rosso R
Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients.
Oncology 1993;50(6):460-5.
1993: Biadi O; Mengozzi G; Gherarducci G; Strata G; Mariani M; Baldini F; Giannessi P G; Surbone A; Conte P F
Evaluation of taxol cardiotoxicity in metastatic breast cancer.
Annals of the New York Academy of Sciences 1993;698():403-5.
1993: Valenti M; Cimoli G; Mariani G L; Conte P F; Parodi S; Russo P
Potentiation of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation.
Biochemical pharmacology 1993;46(7):1199-206.
1993: Spagnesi S; Ducci F; Laddaga M; Falcone A; Conte P F; Pandolfi A; Stampino C G
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region.
Tumori 1993;79(4):250-3.
1993: Falcone A; Cianci C; Ricci S; Brunetti I; Bertuccelli M; Conte P F
Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
Cancer 1993;72(2):564-8.
1993: Chiara S; Campora E; Merlini L; Simoni C; Iskra L; Odicino F; Ragni N; Conte P F; Rosso R
Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens.
European journal of cancer (Oxford, England : 1990) 1993;29A(4):652.
1993: Repetto L; Pace M; Mammoliti S; Bruzzone M; Chiara S; Oliva C; Guido T; Conte P F; Campora E; Rubagotti A
The impact of received dose intensity on the outcome of advanced ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(2):181-4.
1992: Alama A; Merlo F; Chiara S; Muttini M P; Guido T; Nicolò G; Conte P F; Ragni N
Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma.
European journal of cancer (Oxford, England : 1990) 1992;28A(6-7):1079-80.
1992: Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte P F; Fioretti P; Foglia G; Ragni N
Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
European journal of gynaecological oncology 1992;13(1 Suppl):36-9.
1991: Chiara S; Orsatti M; Franzone P; Scarpati D; Bruzzone M; Repetto L; Vitale V; Conte P F; Rosso R
Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1991;3(6):340-4.
1991: Repetto L; Chiara S; Guido T; Bruzzone M; Oliva C; Ragni N; Conte P F; Rosso R
Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.
Anticancer research 1991;11(4):1641-3.
1991: Conte P F; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(4):658-63.
1991: Vigani A; Chiara S; Miglietta L; Repetto L; Conte P F; Cimoli G; Morelli L; Billi G; Parodi S; Russo P
Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity.
Gynecologic oncology 1991;41(1):52-5.
1990: Conte P F; Gardin G; Pronzato P; Miglietta L; Rosso R; Amadori D; Gentilini P; Monzeglio C; Gallotti P; Demicheli R
In vivo manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results.
The Journal of steroid biochemistry and molecular biology 1990;37(6):1103-8.
1990: Repetto L; Chiara S; Mammoliti S; Guido T; Bruzzone M; Secondo V; Donadio G; Odicino F; Ragni N; Conte P F
Crossover study with cisplatin or carboplatin in advanced ovarian cancer.
Gynecologic oncology 1990;39(2):146-9.
1990: Pronzato P; Brema F; Amoroso D; Bertelli G; Conte P F; Martini M C; Pastorino G; Rosso R
Megestrol acetate: phase II study of a single daily administration in advanced breast cancer.
Breast cancer research and treatment 1990;17(1):51-4.
1990: Bruzzone M; Repetto L; Chiara S; Campora E; Conte P F; Orsatti M; Vitale V; Rubagotti A; Rosso R
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look.
Gynecologic oncology 1990;38(3):392-5.
1990: Repetto L; Chiara S; Pace M; Guido T; Bruzzone M; Oliva C; Murolo C; Conte P F; Rosso R
Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens.
Tumori 1990;76(3):274-7.
1990: Guenzi M; Scarpati D; Corvò R; Sanguineti G; Gardin G; Conte P F; Vitale V
[The role of radiotherapy in the multimodal treatment of locally advanced breast carcinoma]
La Radiologia medica 1990;79(5):534-8.
1990: Rosso R; Alama A; Repetto L; Conte P F
Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer.
Cancer chemotherapy and pharmacology 1990;26 Suppl():S43-4.
1990: Campora E; Vidali A; Mammoliti S; Ragni N; Conte P F
Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide.
European journal of gynaecological oncology 1990;11(3):181-3.
1990: Alama A; Costantini M; Repetto L; Conte P F; Serrano J; Nicolin A; Barbieri F; Ardizzoni A; Bruzzi P
Thymidine labelling index as prognostic factor in resected non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(5):622-5.
1989: Conte P F; Alama A; Rubagotti A; Chiara S; Nicolin A; Nicolò; Rosso R; Gaddi M; Ghiringhello B; Tomao S
Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival.
Cancer 1989;64(6):1188-91.
1989: Pronzato P; Amoroso D; Bertelli G; Conte P F; Cusimano M P; Ciottoli G B; Gulisano M; Lionetto R; Rosso R
Phase II study of lonidamine in metastatic breast cancer.
British journal of cancer 1989;59(2):251-3.
1989: Onetto M; Bruzzone M; Conte P F; Ruvolo M; Conio A; Chiara S; Falcone A; Bentivoglio G; Serra G E; Paganuzzi M
Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker.
Oncology 1989;46(2):117-22.
1989: Canavese G; Catturich A; Battistini G; Caroti C; Pronzato P; Gardin G; Amoroso D; Bertelli G; Conte P F; Tomao S
The role of surgery in the combined treatment of locally advanced breast cancer.
Oncology 1989;46(6):353-6.
1988: Bertelli G; Pronzato P; Amoroso D; Cusimano M P; Conte P F; Montagna G; Bertolini S; Rosso R
Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels.
Breast cancer research and treatment 1988;12(3):307-10.
1988: Chiara S; Consoli R; Falcone A; Bruzzone M; Foglia G; Ragni N; Conte P F
Cisplatin and 5-fluorouracil in advanced and recurrent cervical cancer.
Tumori 1988;74(4):471-4.
1988: Amoroso D; Pronzato P; Bertelli G; Gallotti P; Pastorino G; Cusimano M P; Merlano M; Conte P F; Rosso R
Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study.
Breast cancer research and treatment 1988;11(3):269-71.
1988: Conte P F; Bruzzone M; Chiara S; Rosso R; Giaccone G; Carnino F; Guercio E; Ragni N; Foglia G; Bentivoglio G
Carboplatin (JM 8), adriamycin and cyclophosphamide (JAC) in advanced ovarian carcinoma: a pilot study.
Tumori 1988;74(2):217-20.
1988: Falcone A; Chiara S; Franzone P; Vitale V; Scarpati D; Bruzzone M; Carnino F; Conte P F
Moving-strip abdomino-pelvic radiotherapy after cis-platinum-based chemotherapy and second-look operation. A feasibility study in advanced ovarian cancer.
American journal of clinical oncology 1988;11(1):16-20.
1988: Chiara S; Foglia G; Odicino F; Graziani A; Conte P F; Ragni N; Fulcheri E; Pescetto G
Uterine sarcomas: a clinicopathologic study.
Oncology 1988;45(6):428-33.
1987: Conte P F; Alama A; Bertelli G; Canavese G; Carnino F; Catturich A; Di Marco E; Gardin G; Jacomuzzi A; Monzeglio C
Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results.
International journal of cancer. Journal international du cancer 1987;40(4):490-4.
1987: Pronzato P; Amoroso D; Ardizzoni A; Bertelli G; Conte P F; Michelotti A; Rosso R
A phase II study with danazol in metastatic breast cancer.
American journal of clinical oncology 1987;10(5):407-9.
1987: Chiara S; Conte P F; Bruzzone M; Falcone A; Sertoli M R; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(5):380-3.
1987: Pronzato P; Amoroso D; Ardizzoni A; Bertelli G; Canobbio L; Conte P F; Cusimano M P; Fusco V; Gulisano M; Lionetto R
Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer.
American journal of clinical oncology 1987;10(5):404-6.
1987: Conte P F; Rubagotti A; Falcone A; Gardin G; Nicolin A; Pronzato P; Rosso R; Amadori D; Gentilini P; Sismondi P
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(2 Suppl):712-3.
1987: Conte P F; Pronzato P; Rubagotti A; Alama A; Amadori D; Demicheli R; Gardin G; Gentilini P; Jacomuzzi A; Lionetto R
Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(3):339-47.
1987: Repetto L; Pronzato P; Ardizzoni A; Bertelli G; Gulisano M; Amoroso D; Gardin G; Fusco V; Falcone A; Conte P F
Metastatic breast cancer: an analysis of prognostic factors in patients treated with aminoglutethimide.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(1):66-72.
1986: Conte P F; Bruzzone M; Chiara S; Sertoli M R; Daga M G; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(6):965-71.
1986: Alama A; Conte P F; Di Marco E; Favoni R E; Nicolin A
Proliferative activity of human solid tumors evaluated by thymidine labeling index and primer-dependent alpha-DNA polymerase.
Oncology 1986;43(6):385-9.
1986: Conte P F; Alama A; Di Marco E; Canavese G; Rosso R; Nicolin A
Cytokinetic parameters of locally advanced human breast cancer treated with diethylstilbestrol and chemotherapy.
Basic and applied histochemistry 1986;30(2):227-31.
1985: Bruzzone M; Conte P F; Chiara S; Carnino F; Giaccone G; Conio A; Bentivoglio G; Pescetto G; Rosso R
High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1985;4(2):139-42.
1985: Conte P F; Sertoli M R; Bruzzone M; Rubagotti A; Rosso R; Bentivoglio G; Conio A; Pescetto G
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
Gynecologic oncology 1985;20(3):290-7.
1984: Conte P F; Alama A; Favoni R; Trave F; Rosso R; Nicolin A
Timed sequential chemotherapy following drug-induced kinetic recruitment in refractory ovarian cancer.
European journal of cancer & clinical oncology 1984;20(8):1039-43.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Pier Franco Conte

Research Profile (preview)

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Pier Franco Conte (preview)

All Publications